Revolutionizing Cancer Research: The Impact of Artificial Intelligence in Digital Biobanking.
artificial intelligence
biobank
cancer research
digital pathology
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
16 Sep 2023
16 Sep 2023
Historique:
received:
08
08
2023
revised:
05
09
2023
accepted:
12
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Biobanks are vital research infrastructures aiming to collect, process, store, and distribute biological specimens along with associated data in an organized and governed manner. Exploiting diverse datasets produced by the biobanks and the downstream research from various sources and integrating bioinformatics and "omics" data has proven instrumental in advancing research such as cancer research. Biobanks offer different types of biological samples matched with rich datasets comprising clinicopathologic information. As digital pathology and artificial intelligence (AI) have entered the precision medicine arena, biobanks are progressively transitioning from mere biorepositories to integrated computational databanks. Consequently, the application of AI and machine learning on these biobank datasets holds huge potential to profoundly impact cancer research. In this paper, we explore how AI and machine learning can respond to the digital evolution of biobanks with flexibility, solutions, and effective services. We look at the different data that ranges from specimen-related data, including digital images, patient health records and downstream genetic/genomic data and resulting "Big Data" and the analytic approaches used for analysis. These cutting-edge technologies can address the challenges faced by translational and clinical research, enhancing their capabilities in data management, analysis, and interpretation. By leveraging AI, biobanks can unlock valuable insights from their vast repositories, enabling the identification of novel biomarkers, prediction of treatment responses, and ultimately facilitating the development of personalized cancer therapies. The integration of biobanking with AI has the potential not only to expand the current understanding of cancer biology but also to pave the way for more precise, patient-centric healthcare strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Biobanks are vital research infrastructures aiming to collect, process, store, and distribute biological specimens along with associated data in an organized and governed manner. Exploiting diverse datasets produced by the biobanks and the downstream research from various sources and integrating bioinformatics and "omics" data has proven instrumental in advancing research such as cancer research. Biobanks offer different types of biological samples matched with rich datasets comprising clinicopathologic information. As digital pathology and artificial intelligence (AI) have entered the precision medicine arena, biobanks are progressively transitioning from mere biorepositories to integrated computational databanks. Consequently, the application of AI and machine learning on these biobank datasets holds huge potential to profoundly impact cancer research.
METHODS
METHODS
In this paper, we explore how AI and machine learning can respond to the digital evolution of biobanks with flexibility, solutions, and effective services. We look at the different data that ranges from specimen-related data, including digital images, patient health records and downstream genetic/genomic data and resulting "Big Data" and the analytic approaches used for analysis.
RESULTS
RESULTS
These cutting-edge technologies can address the challenges faced by translational and clinical research, enhancing their capabilities in data management, analysis, and interpretation. By leveraging AI, biobanks can unlock valuable insights from their vast repositories, enabling the identification of novel biomarkers, prediction of treatment responses, and ultimately facilitating the development of personalized cancer therapies.
CONCLUSIONS
CONCLUSIONS
The integration of biobanking with AI has the potential not only to expand the current understanding of cancer biology but also to pave the way for more precise, patient-centric healthcare strategies.
Identifiants
pubmed: 37763157
pii: jpm13091390
doi: 10.3390/jpm13091390
pmc: PMC10532470
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Front Mol Biosci. 2022 Aug 26;9:967310
pubmed: 36090048
Clin Exp Immunol. 2011 Jan;163(1):33-49
pubmed: 20939860
J Pers Med. 2022 Nov 16;12(11):
pubmed: 36422090
JAMA. 2018 Dec 4;320(21):2199-2200
pubmed: 30398550
Biopreserv Biobank. 2012 Jun;10(3):239-44
pubmed: 24835062
Front Digit Health. 2021 Jun 14;3:628646
pubmed: 34713101
Diagn Cytopathol. 2022 Jan;50(1):34-45
pubmed: 34677909
BMC Med Inform Decis Mak. 2019 Aug 23;19(1):171
pubmed: 31443706
N Engl J Med. 2018 Jul 26;379(4):305-307
pubmed: 29898371
J Clin Med. 2019 Mar 14;8(3):
pubmed: 30875745
Healthcare (Basel). 2022 Sep 07;10(9):
pubmed: 36141326
EPMA J. 2016 Feb 22;7:4
pubmed: 26904153
Cancer Treat Res. 2019;178:265-283
pubmed: 31209850
NPJ Digit Med. 2020 Jul 9;3:93
pubmed: 32665978
Semin Cancer Biol. 2018 Oct;52(Pt 2):151-157
pubmed: 29990622
Bioethics. 2016 May;30(4):260-71
pubmed: 26307361
J Glob Health. 2018 Dec;8(2):020303
pubmed: 30405904
Lancet Oncol. 2019 May;20(5):e253-e261
pubmed: 31044723
J Transl Med. 2019 May 22;17(1):172
pubmed: 31118074
Oncol Rev. 2018 May 11;12(1):357
pubmed: 30057691
NPJ Digit Med. 2022 Jul 22;5(1):102
pubmed: 35869179
BMC Bioinformatics. 2020 Nov 30;21(1):549
pubmed: 33256603
Yearb Med Inform. 2022 Aug;31(1):152-160
pubmed: 36463873
Oncol Res. 2022 Aug 31;29(4):229-233
pubmed: 37303941
Biopreserv Biobank. 2009 Sep;7(3):143-50
pubmed: 24835880
N Biotechnol. 2023 May 25;74:16-24
pubmed: 36754147
J Pathol. 2019 Nov;249(3):286-294
pubmed: 31355445
Virchows Arch. 2021 Aug;479(2):233-246
pubmed: 34255145
Sci Rep. 2020 Aug 12;10(1):13652
pubmed: 32788635
Pathol Res Pract. 2023 May;245:154488
pubmed: 37116365
Per Med. 2016 Jul;13(4):283-285
pubmed: 29749809
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
Appl Clin Inform. 2010 Nov 24;1(4):419-29
pubmed: 23616851
Mod Pathol. 2022 Jan;35(1):23-32
pubmed: 34611303
Nat Rev Nephrol. 2020 Nov;16(11):669-685
pubmed: 32848206
J Clin Med. 2022 Jul 15;11(14):
pubmed: 35887873
Pathol Res Pract. 2020 Sep;216(9):153040
pubmed: 32825928
BioTech (Basel). 2021 Jul 02;10(3):
pubmed: 35822767
Front Med (Lausanne). 2019 Jun 26;6:141
pubmed: 31294024
J Transl Med. 2019 Nov 14;17(1):374
pubmed: 31727094
J Transl Med. 2021 Dec 4;19(1):493
pubmed: 34863191
Neuroimage. 2021 Nov 1;241:118409
pubmed: 34293465
Front Cell Dev Biol. 2019 Oct 22;7:246
pubmed: 31696117
Diagnostics (Basel). 2022 May 09;12(5):
pubmed: 35626333
Am J Hum Genet. 2020 Jan 2;106(1):3-12
pubmed: 31866045
Sci Transl Med. 2014 Apr 30;6(234):234cm3
pubmed: 24786321
J Hum Genet. 2021 Jan;66(1):61-65
pubmed: 32782383
Oncologist. 2023 Feb 8;28(2):93-104
pubmed: 36200788
Nat Med. 2020 Sep;26(9):1364-1374
pubmed: 32908283
Mhealth. 2017 Sep 14;3:38
pubmed: 29184890
Acad Pathol. 2022 Jul 31;9(1):100047
pubmed: 35941875
BMC Med Ethics. 2006 Apr 06;7:E4
pubmed: 16600040
Am J Hum Genet. 2020 Aug 6;107(2):222-233
pubmed: 32589924
Lancet Digit Health. 2020 Oct;2(10):e549-e560
pubmed: 33328049
Proteomics. 2019 Nov;19(21-22):e1800485
pubmed: 31321888
Chem Rev. 2019 Sep 25;119(18):10520-10594
pubmed: 31294972
Sci Rep. 2020 Jun 29;10(1):10521
pubmed: 32601354
Front Pharmacol. 2021 Sep 30;12:720694
pubmed: 34658859
Healthcare (Basel). 2023 Jun 22;11(13):
pubmed: 37444659